

# HSE – Medicines Management Programme (MMP)



The HSE-Medicines Management Programme (MMP) aims to promote safe, effective and cost-effective prescribing in Ireland. Information on MMP initiatives is available on [www.hse.ie/yourmedicines](http://www.hse.ie/yourmedicines)

## HSE-MMP Preferred Drugs

Therapeutic Area	☑ HSE-MMP Preferred Drug
Angiotensin-Converting Enzyme (ACE) inhibitor	<b>Ramipril</b>
Angiotensin-II Receptor Blocker (ARB)	<b>Candesartan</b>
Beta Blocker	<b>Bisoprolol</b>
Calcium Channel Blocker (CCB)	<b>Amlodipine</b>
Oral Anticoagulant	<b>Warfarin</b>
Direct Oral Anticoagulant (DOAC)	<b>Apixaban</b>
Proton Pump Inhibitor (PPI)	<b>Pantoprazole</b>
Selective Serotonin Reuptake Inhibitor (SSRI)	<b>Sertraline</b>
Serotonin Noradrenaline Reuptake Inhibitor (SNRI)	<b>Venlafaxine</b>
Statin	<b>Atorvastatin</b>
Urology (Urinary incontinence, frequency, overactive bladder)	<b>Tolterodine extended release</b>

### HSE-MMP Preferred Standard Oral Nutritional Supplements (ONS)

**List A:** Powdered ONS (*Aymes Shake/with Fibre, Aymes Shake Compact, Complian Shake, Ensure Shake, Foodlink Complete/with Fibre, Fresubin Powder Extra*) and Compact & Mini Drink sip feeds (*Altraplen Compact, Ensure Compact, Fortisip Compact/with Fibre, Fresubin 2Kcal Mini Drink/with Fibre*).

Standard ONS Prescribing Pathway for Adults Living in the Community is available on [www.hse.ie/yourmedicines](http://www.hse.ie/yourmedicines)

### HSE-MMP Preferred Blood Glucose Test Strips (BGTS)

The HSE-MMP has identified preferred BGTS with associated meters for adults with type 1 and type 2 diabetes mellitus. This list was updated at the beginning of 2023. A list of preferred BGTS with associated meters was identified to ensure that there are a variety of options available to patients and prescribers. The HSE-MMP recognises the potential for a reduction in expenditure on BGTS by increased utilisation of preferred BGTS. Further information is available on [www.hse.ie/yourmedicines](http://www.hse.ie/yourmedicines)

### Prescribing and Cost Guidance: Dry Eye Syndrome

The HSE-MMP has completed a review of the treatment of dry eye syndrome (DES) and published a Prescribing and Cost Guidance document. The guidance document and associated tips and tools recommend first-line preparations based on clinical evidence and cost, and are intended to promote best practice and aid appropriate prescribing for DES. These documents are available on [www.hse.ie/yourmedicines](http://www.hse.ie/yourmedicines)

### HSE-MMP Managed Access Processes

Reimbursement application systems are in place for a number of medicines through PCRS online services, including:

- **Xarelto® (rivaroxaban) 2.5 mg film-coated tablets:** reimbursement is supported for a defined subgroup of patients for prevention of atherothrombotic events in adults with coronary artery disease or symptomatic peripheral artery disease at high risk of ischaemic events, when co-administered with aspirin.
- **Saxenda® (liraglutide) 6 mg/ml solution for injection in pre-filled pen:** reimbursement is supported for a defined subgroup of the licensed population for adults, as an adjunct to a reduced-calorie diet and increased physical activity for weight management, with an initial body mass index of  $\geq 35$  kg/m<sup>2</sup> with prediabetes and high-risk of cardiovascular disease.

Managed access protocols are in place for a number of medicines; these are available under *Managed Access Protocols* at [www.hse.ie/yourmedicines](http://www.hse.ie/yourmedicines)